Tekmira Pharmaceuticals Corp (TKMR) (TKMR)

[surf1944]

8:03AM Tekmira Pharma's collaborators at the National Cancer Institute present preclinical data at the AACR; preclinical results indicate that a statistically significant decrease in tumor size was observed in the animals treated with either CSN5 siRNA or a combination of CSN5 and WEE1 siRNA (TKMR) 4.58 : Co announced that its collaboration partner, the National Cancer Institute, will present preclinical data at the annual meeting of the American Association for Cancer Research in a poster session beginning at 8:00 am ET today entitled "Nanoparticle-Based Combinatorial siRNA Therapy against Human Hepatocellular Carcinoma."

The preclinical results summarized in the poster indicate that a statistically significant decrease in tumor size was observed in the animals treated with either CSN5 siRNA or a combination of CSN5 and WEE1 siRNA. The results also indicate that the treatment does not affect the global gene expression in the surrounding liver following siRNA therapy compared to that seen in the tumor tissue, supporting the tumor-specific nature of the effect. Tekmira has an ongoing collaboration with the NCI to identify novel cancer genes for RNAi applications to meet unmet needs